These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12967752

  • 1. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
    Rhomberg PR, Jones RN, MYSTIC Program (USA) Study Group.
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):365-72. PubMed ID: 12967752
    [Abstract] [Full Text] [Related]

  • 2. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [Abstract] [Full Text] [Related]

  • 7. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    J Chemother; 2005 Oct; 17(5):459-69. PubMed ID: 16323433
    [Abstract] [Full Text] [Related]

  • 8. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [Abstract] [Full Text] [Related]

  • 9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 10. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [Abstract] [Full Text] [Related]

  • 11. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [Abstract] [Full Text] [Related]

  • 12. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 13. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
    Turner PJ.
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
    [Abstract] [Full Text] [Related]

  • 14. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
    Rhomberg PR, Jones RN, Sader HS, MYSTIC Programme (US) Study Group.
    Int J Antimicrob Agents; 2004 Jan; 23(1):52-9. PubMed ID: 14732314
    [Abstract] [Full Text] [Related]

  • 15. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S, Garcia-Rodriguez JA.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [Abstract] [Full Text] [Related]

  • 16. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).
    Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):279-85. PubMed ID: 12730000
    [Abstract] [Full Text] [Related]

  • 17. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P, Hasçelik G, Unal S.
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK, Kuti JL, Nicolau DP.
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B, Goic-Barisic I, Budimir A, Tonkic M, Mihajkevic LJ, Novak A, Sviben M, Plecko V, Punda-Polic V, Kalenic S.
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [Abstract] [Full Text] [Related]

  • 20. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN, Mendes C, Turner PJ, Masterton R.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.